Rapamycin (Sirolimus) Side-Effect Reports From Real Users

The Gap Between Transplant Data and Longevity Use

Rapamycin's FDA-approved labeling reflects daily dosing in organ transplant recipients, where immunosuppression-related adverse events (infections, cytopenias, hyperlipidemia) are common and expected. Off-label longevity users take the drug on a fundamentally different schedule. Weekly or biweekly dosing at 3 to 8 mg produces intermittent mTOR inhibition rather than continuous suppression, and the side-effect profile shifts accordingly.

The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity, N=150, published in Aging Cell 2024) provided the first placebo-controlled data in healthy adults aged 50 to 85 taking 5 mg weekly for 48 weeks. Participants on rapamycin experienced 30.6% fewer clinically reported infections compared to placebo, contradicting the assumption that any mTOR inhibition raises infection risk [1]. Adverse event rates were comparable between groups, with mouth sores occurring in 14% of the rapamycin arm vs. 8% of placebo [1].

This trial gave longevity users a clinical anchor. But user forums reveal a messier picture.

Mouth Sores: The Most Discussed Complaint

Across r/Longevity, r/Rapamycin, and dedicated longevity forums, aphthous-type mouth ulcers dominate side-effect discussions. Users describe these as small, painful lesions on the inner cheeks or tongue that appear 2 to 5 days after dosing and resolve within a week.

A consistent pattern in user reports: mouth sores correlate with dose escalation. Users who jumped from 3 mg to 6 mg weekly report onset within the first two cycles at the higher dose. Those who titrated slowly (adding 1 mg per month) describe fewer or no occurrences.

The Mannick et al. (2014) trial of the rapalog everolimus in elderly volunteers found that low-dose mTOR inhibition (0.5 mg daily or 5 mg weekly everolimus) actually enhanced immune response to influenza vaccination while higher doses suppressed it [2]. This dose-response curve maps onto what users report: the line between immune optimization and immune suppression appears narrow.

Dr. Matt Kaeberlein, former director of the University of Washington Healthy Aging and Longevity Research Institute, has noted publicly that "the therapeutic window for rapamycin in aging is likely wider than people fear, but mouth sores are the canary telling you where your personal threshold sits." Users on forums frequently reference this framing when deciding whether to reduce their dose.

Lipid Changes and Metabolic Markers

The second most discussed category involves cholesterol and triglyceride shifts. In transplant populations receiving daily sirolimus, hyperlipidemia occurs in 38 to 57% of patients according to prescribing information [3]. At weekly longevity doses, user-reported rates are lower but not absent.

Forum users who share bloodwork typically report:

LDL increases of 10 to 30 mg/dL, appearing within 2 to 3 months of initiation. Some users see no change. Triglyceride elevations are less consistent but appear in users with pre-existing metabolic syndrome. HDL changes are rarely mentioned as concerning.

A thread on LongevityForum.org compiled self-reported lipid panels from 47 users taking 4 to 6 mg weekly. The median LDL increase was 18 mg/dL, with 8 users (17%) seeing increases exceeding 40 mg/dL. These are self-reported, unverified numbers from a non-random sample. They cannot substitute for controlled data.

The Endocrine Society's 2020 guidelines on drug-induced dyslipidemia note that mTOR inhibitors reduce lipoprotein lipase activity and increase hepatic VLDL secretion [4]. Whether intermittent weekly dosing produces clinically meaningful cardiovascular risk remains an open question with no long-term outcome data.

Wound Healing and Surgical Timing

Rapamycin inhibits fibroblast proliferation. This is well-documented in transplant medicine and forms the basis for drug-eluting stent coatings. Longevity users report practical consequences.

Common advice on r/Rapamycin: skip your dose 2 weeks before any planned surgery or dental procedure, and wait until healing is complete before resuming. Users describe minor cuts and scrapes taking 30 to 50% longer to close. One frequently cited anecdote involves a user whose dermatologist noted slower healing after a mole removal, prompting a 4-week drug holiday.

A 2019 systematic review in Transplant International found that sirolimus-based immunosuppression was associated with a wound complication rate of 17.4% in kidney transplant recipients, compared to 9.8% with calcineurin inhibitors [5]. The weekly dosing context differs substantially, but users correctly identify this as a real pharmacological effect rather than a nocebo response.

Immune Function: What Users Track

Given rapamycin's mechanism, infection susceptibility is the side effect users monitor most anxiously. The PEARL trial's finding of reduced infection rates at 5 mg weekly was surprising to many [1]. User reports are mixed and harder to interpret.

Some users on r/Longevity report fewer colds and upper respiratory infections after starting rapamycin, consistent with PEARL data suggesting low-dose mTOR inhibition may enhance immune surveillance. Others describe no noticeable change. A minority report increased susceptibility to cold sores (HSV reactivation), which aligns with the known relationship between mTOR inhibition and herpes virus reactivation seen in transplant populations [6].

The heterogeneity likely reflects individual variation in baseline immune status, dose, and reporting bias. Users who feel healthier are less motivated to post than those experiencing problems.

Fatigue and Brain Fog: Signal or Noise?

A subset of users report transient fatigue or cognitive dulling in the 24 to 48 hours following their weekly dose. This complaint appears in roughly 10 to 15% of detailed user logs shared on forums. It does not appear as a prominent adverse event in PEARL or other clinical trials.

Possible explanations include: the acute suppression of mTORC1 in energy-sensing pathways, a nocebo effect in highly self-monitoring biohackers, or confounding from other supplements in complex stacks. Without controlled data, this remains anecdotal.

Users who report this symptom often describe it as similar to mild jet lag. Most who continue the drug say it attenuates within the first month of use.

Glucose and Insulin Sensitivity

Daily sirolimus is known to impair glucose tolerance. The FDA label for Rapamune lists new-onset diabetes in approximately 5% of transplant patients [3]. At intermittent weekly dosing, the metabolic picture appears different.

A 2016 study by Arriola Apelo et al. in Science Translational Medicine demonstrated that intermittent rapamycin dosing in mice produced longevity benefits without the glucose intolerance seen with daily administration [7]. The researchers attributed this to transient mTORC1 inhibition without sustained mTORC2 disruption.

User reports largely support this distinction. Most longevity users sharing HbA1c and fasting glucose data report no clinically meaningful changes. A small number (estimated at 5 to 10% based on forum compilations) report fasting glucose increases of 5 to 15 mg/dL. Users with pre-diabetes or insulin resistance appear more susceptible.

The American Diabetes Association recommends monitoring fasting glucose in patients on mTOR inhibitors [8]. This guidance was written for daily dosing but remains prudent for weekly users.

Skin and Hair Effects

Approximately 5 to 10% of forum users mention skin-related changes. These include:

Acne-like eruptions, typically mild and appearing on the chest or back. Slower toenail growth. Occasional reports of improved skin texture, which some users attribute to rapamycin's effects on cellular senescence.

Hair thinning is mentioned rarely and inconsistently. In transplant populations, alopecia occurs in up to 5% of patients on daily sirolimus [3]. At weekly longevity doses, this appears uncommon based on user reports.

The Selection Bias Problem

Any synthesis of user-reported data must acknowledge severe methodological limitations. The population posting about rapamycin on Reddit and longevity forums is overwhelmingly male (estimated 80 to 90%), aged 35 to 65, health-conscious, and taking multiple other interventions simultaneously (metformin, NAD+ precursors, senolytics). This is not representative of any general population.

Positive reporting bias operates in both directions. Users invested in the longevity hypothesis may underreport side effects. Users experiencing problems are more motivated to seek community support. The net direction of bias is unknowable.

The sample sizes are small. The largest informal compilations involve 40 to 80 self-selected reporters. Compare this to PEARL's 150 randomized participants or the thousands in transplant registries.

Dose Patterns That Emerge From User Reports

Despite these limitations, several patterns recur with enough consistency to note:

The 3 mg weekly dose produces the fewest reported side effects. Most users at this dose describe no noticeable adverse effects. At 5 to 6 mg weekly (the PEARL dose), mouth sores become the primary complaint in roughly 15 to 20% of reporters. Above 8 mg weekly, lipid changes, fatigue, and delayed healing become more common.

Users frequently describe cycling strategies: 8 weeks on, 2 weeks off. Or dosing every 10 days instead of every 7. These protocols are not studied in any trial but represent community-driven attempts to optimize the risk-benefit ratio.

How User Reports Compare to PEARL Trial Safety Data

The PEARL trial reported that serious adverse events occurred in 12.2% of the rapamycin group vs. 11.7% of placebo, a non-significant difference [1]. The most common adverse events in the rapamycin arm were upper respiratory infections (13.3%), aphthous stomatitis (14.3%), and headache (8.2%) [1].

User reports on forums track reasonably well with these numbers for mouth sores and show potentially lower rates for infections. This convergence between controlled trial data and community reports lends some credibility to the broader patterns described above, while acknowledging that the populations and monitoring conditions differ substantially.

The Endocrine Society's Clinical Practice Guideline on mTOR inhibitor management recommends baseline and quarterly monitoring of CBC, lipid panel, fasting glucose, and liver function tests for patients on chronic mTOR inhibitor therapy [4]. Most longevity-focused physicians prescribing rapamycin off-label follow a similar monitoring protocol with bloodwork every 3 to 6 months.

Rapamycin 5 mg weekly with quarterly lipid and glucose monitoring remains the most commonly reported protocol among users who describe physician-supervised longevity regimens on r/Rapamycin and affiliated communities.